Sign In

News

All the latest updates from the CIC and its members.
Government announces research changes

Government announces research changes

The Government has recently written to the ACMD about part 2 of their ‘barriers to research’ work, with some notable developments:

  • General: “A new cross-government officials working group will focus on any new issues involving research with controlled drugs while also monitoring the changes following your recommendations.”
  • Recommendation 1: Research using Schedule 1 Controlled Drugs in universities and hospitals be exempt from the need to apply for a Home Office domestic licence and instead to operate in accordance with the requirements of Schedule 2 Controlled Drugs. Government response: “The government agrees with this recommendation in principle subject to operational feasibility”.
  • Recommendation 2: The ACMD recommends that clinical studies using Schedule 1 Controlled Drugs with relevant HRA and MHRA approvals be exempt from the need to apply for a HO domestic licence and instead to operate in accordance with the requirements of Schedule 2 Controlled Drugs. Government response: “The government agrees with this recommendation in principle”.
  • Recommendation 3: The ACMD recommends that organisations that are already exempt from the need to apply for a Home Office domestic licence for the purpose of supplying a university or hospital with Schedule 2–5 Controlled Drugs, be exempt from the need to apply for a Home Office domestic licence for the purpose of supplying a university or hospital with a Schedule 1 Controlled Drug for research purposes. Government response: “The government cannot accept this recommendation as currently presented in the ACMD report…This will therefore be discussed within the cross-government working group, and the ACMD will be asked for further clarification regarding this recommendation if required.”
  • Recommendation 4: The ACMD recommends the HO review the domestic and import/export licence application systems to consider if there are any further options to improve applicant understanding and experience, recognising some applicants are first-time applicants or use the system infrequently. Government response: “The government accepts this recommendation”.
  • Recommendation 5: The ACMD recommends the HO design a framework for the assessment and evaluate the impact of any policy changes to reduce barriers to research associated with Schedule 1 Controlled Drugs. Government response: “The government accepts this recommendation”.

The letter can be viewed in full here.

Related Posts